Le Lézard
Classified in: Health
Subjects: NPT, PDT, FDA

Brain & Behavior Research Foundation Comments on FDA Approval of New Depression Treatment

NEW YORK, March 6, 2019 /PRNewswire/ -- The Brain & Behavior Research Foundation (BBRF) applauds the FDA for its approval of Esketamine nasal spray as a new medication for treatment of resistant depression. 

Committed to alleviating the suffering caused by mental illness by awarding grants that will lead to advances and breakthroughs in scientific research. (PRNewsFoto/Brain & Behavior Research ...)

Dr. Jeffrey Borenstein, a Manhattan psychiatrist and President & CEO of the Brain & Behavior Research Foundation, says, "The approval of Esketamine as a new medication for treatment resistant depression is welcome news for people and their families who are impacted by depression."  

"We are pleased that the Brain & Behavior Research Foundation funding of both early research and ongoing studies on rapid acting antidepressants has helped lead to this development of a new medication for treatment resistant depression," Dr. Borenstein adds.

Dr. Borenstein is available for further commentary on the research and implications of the approval of Esketamine. 

Since 1996, BBRF has awarded 90 grants totaling more than $6.5 million to fund research on rapid acting antidepressants conducted by scientists in the United States and abroad. One of these scientists is BBRF Young Investigator Carla M. Canuso, M.D., of Johnson & Johnson/Janssen R&D, whose paper, "Esketamine Reduced Suicidal Thoughts Within Hours of Treatment" published in the American Journal of Psychiatry in July 2018, was cited as one of the top 12 advances in psychiatric research from a BBRF-funded scientist in 2018. Among other scientists in the field who have received BBRF funding is Dr. Carlos A. Zarate, of the National Institutes of Mental Health, who was one of the early pioneers in the study of ketamine for the treatment of depression.

The Brain & Behavior Research Foundation
The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness. These illnesses include addiction, ADHD, anxiety, autism, bipolar disorder, borderline personality disorder, depression, eating disorders, OCD, PTSD, and schizophrenia. Since 1987, the Foundation has awarded more than $394 million to fund more than 4,700 leading scientists around the world, which has led to over $3.9 billion in additional funding. 100% of every dollar donated for research is invested in our research grants. The Foundation's operating expenses are covered by separate foundation grants.

For more information: The Brain & Behavior Research Foundation


SOURCE Brain & Behavior Research Foundation

These press releases may also interest you

at 13:19
Most people wouldn't attempt to write a memoir before age 40, but Danielle Ripley-Burgess is not like most people. And while her diagnosis of colon cancer at ages 17 and 25 often headline the survivor's story, in her forthcoming book, Blush: How I...

at 13:15
Ocean Bio-Chem, Inc. announced today that its subsidiary, Kinpak Inc., has commissioned a third production line for the manufacturing of its disinfectant/sanitizer product group Performacide®.  Performacide® is an EPA-registered disinfectant that...

at 13:12
Delta Care Rx, one of the nation's leading and innovative pharmacy benefit management companies exclusively serving hospice and serious illness providers, today announced the accelerated roll out of a new tool to ensure hospices can comply with...

at 13:11
Spindletop Pain Management Holdings, LLC, and Tricity Pain Associates, P.A., a leading provider of pain management services, announces that it has acquired Hill Country Pain Associates.  Spindletop Pain Management Holdings partnered with Tricity Pain...

at 13:06
Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, is very pleased that the Sean M Healey & AMG Center for ALS at Mass General announced the first patients have been enrolled into the HEALEY ALS Platform Trial being conducted at...

at 13:05
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) "Relief" today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent...

News published on 6 march 2019 at 06:00 and distributed by: